Ricardo Castillo Velazquez

Dr. Ricardo Castillo Velazquez

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2023 in PeerJ
Verified
Journal Article
Open access
PDF file
RVRicardo Castillo Velazquez
Ricardo Castillo Velazquez
FMFlavio Martínez-Morales
Flavio Martínez-Morales
JCJulio E. Castañeda-Delgado
Julio E. Castañeda-Delgado
MGMariana H. García-Hernández
Mariana H. García-Hernández
VHVerónica Herrera-Mayorga
Verónica Herrera-Mayorga
ELEdgar E. Lara-Ramírez
Edgar E. Lara-Ramírez
Background: Alzheimer’s disease (AD) and type 2 diabetes mellitus (DM2) are chronic degenerative diseases with complex molecular processes that are potentially interconnected. The aim of this work was to predict the potential molecular links between AD and DM2 from different sources of biological information. Materials and Methods: In this work, data mining of nine databases (DisGeNET, Ensembl, OMIM, Protein Data Bank, The Human Protein Atlas, UniProt, Gene Expression Omnibus, Human Cell Atlas, and PubMed) was performed to identify gene and protein information that was shared in AD and DM2. Next, the information was mapped to human protein-protein interaction (PPI) networks based on experimental data using the STRING web platform. Then, gene ontology biological process (GOBP) and pathway analyses with EnrichR showed its specific and shared biological process and pathway deregulations. Finally, potential biomarkers and drug targets were predicted with the Metascape platform. Results: A total of 1,551 genes shared in AD and DM2 were identified. The highest average degree of nodes within the PPI was for DM2 (average = 2.97), followed by AD (average degree = 2.35). GOBP for AD was related to specific transcriptional and translation genetic terms occurring in neurons cells. The GOBP and pathway information for the association AD-DM2 were linked mainly to bioenergetics and cytokine signaling. Within the AD-DM2 association, 10 hub proteins were identified, seven of which were predicted to be present in plasma and exhibit pharmacological interaction with monoclonal antibodies in use, anticancer drugs, and flavonoid derivatives. Conclusion: Our data mining and analysis strategy showed that there are a plenty of biological information based on experiments that links AD and DM2, which could provide a rational guide to design further diagnosis and treatment for AD and DM2.

Verified
Journal Article
Open access
PDF file
DADiego Armando Alvarado-Camacho
Diego Armando Alvarado-Camacho
RVRicardo Castillo Velazquez
Ricardo Castillo Velazquez
AGAngelica Judith Granados-López
Angelica Judith Granados-López
HHHiram Hernández-López
Hiram Hernández-López
YLYamile Lopez
Yamile Lopez
JLJesús Adrián López
Jesús Adrián López
Cervical cancer remains a significant cause of cancer-related mortality among women, particularly in low- and middle-income countries. High-throughput technologies, such as microarrays, have facilitated the comprehensive analysis of gene expression profiles in cervical cancer, enabling the identification of key differentially expressed genes (DEGs) involved in its pathogenesis. The publicly available microarray datasets, including GSE39001, GSE9750, GSE7803, GSE6791, GSE63514, and GSE52903 in combination with bioinformatics database predictions, were used to identify differential expression genes, potential biomarkers, and therapeutic targets for cervical cancer; additionally, we undertook bioinformatic analysis to determine gene ontology and possible miRNA targets related to our DEGs. Our analysis revealed several DEGs significantly associated with cervical cancer progression, such as cell death, regulation of DNA replication, protein binding processes, and transcription factors. The most relevant transcription factors (TFs) identified were SP1, ELF3, E2F1, TP53, RELA, HDAC, and FOXM1. Importantly, the DEGs with more important changes were 11 coding genes that were upregulated (KIF4A, MCM5, RFC4, PLOD2, MMP12, PRC1, TOP2A, MCM2, RAD51AP1, KIF20A, AIM2) and 14 that were downregulated (CXCL14, KRT1, KRT13, MAL, SPINK5, EMP1, CRISP3, ALOX12, CRNN, SPRR3, PPP1R3C, IVL, CFD, CRCT1), which were associated with cervical cancer. Interestingly, hub proteins KIF4A, NUSAP1, BUB1B, CEP55, DLGAP5, NCAPG, CDK1, MELK, KIF11, and KIF20A were found to be potentially regulated by several miRNAs, including miR-107, miR-124-3p, miR-147a, miR-16-5p, miR-34a-5p, miR-34c-5p, miR-126-3p, miR-10b-5p, miR-23b-3p, miR-200b-3p, miR-138-5p, miR-203a-3p, miR-214-3p, and let-7b-5p. The relationship between these genes highlights their potential as candidate biomarkers for further research in treatment, diagnosis, and prognosis.

17 September 2025 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
SRSofía Ruiz-Hernández
Sofía Ruiz-Hernández
FOFátima de Lourdes Ochoa-González
Fátima de Lourdes Ochoa-González
JCJulio E. Castañeda-Delgado
Julio E. Castañeda-Delgado
OGOthir Gidalti Galicia-Cruz
Othir Gidalti Galicia-Cruz
RVRicardo Castillo Velazquez
Ricardo Castillo Velazquez
ELEdgar E. Lara-Ramírez
Edgar E. Lara-Ramírez
Peptidyl arginine deiminase 4 (PAD4) catalyzes both normal and abnormal citrullination of interacting protein partners, affecting gene regulation and being associated with diseases such as Alzheimer's, cancer, and rheumatoid arthritis (RA).

1 July 2025 in Current Alzheimer Research
Verified
Journal Article
Closed access
PDF file
RVRicardo Castillo Velazquez
Ricardo Castillo Velazquez
JCJulio E. Castaneda-Delgado
Julio E. Castaneda-Delgado
MGMariana H. Garcia-Hernandez
Mariana H. Garcia-Hernandez
BRBruno Rivas-Santiago
Bruno Rivas-Santiago
SRSofia Ruiz-Hernandez
Sofia Ruiz-Hernandez
ELEdgar E. Lara-Ramirez
Edgar E. Lara-Ramirez
Introduction: Type 2 diabetes mellitus (T2D) is a known risk factor for developing Alzheimer’s disease (AD). Recent research shows that both diseases share complex and related pathophysiological processes. Network medicine approaches can help to elucidate common dysregulated processes among different diseases, such as AD and T2D. Thus, the aim of this work was to determine differentially expressed genes (DEGs) in AD and T2D and to apply a network medicine approach to identify the microRNAs (miRNAs) involved in the AD-T2D association. Methods: Gene expression microarray data sets consisting of 384 control samples and 399 samples belonging to AD and T2D disease were analyzed to obtain DEGs shared by both diseases; the miRNAs associated with these DEGs were predicted using a network medicine approach. Finally, potential small molecules targeting these potentially deregulated miRNAs were identified. Results: AD and T2D shared a small subset of 82 downregulated DEGs. These genes were significantly associated (p < 0.01) with the ontology terms of chemical synaptic deregulation. DEGs were associated with 12 miRNAs expressed in specific tissues for AD and T2D. Such miRNAs were also primarily associated with the ontology terms related to synaptic deregulation and cancer, and AKT signaling pathways. Steroid anti-inflammatory drugs, antineoplastics, and glucose metabolites were predicted to be potential regulators of the 12 shared miRNAs. Discussion: The network medicine approach integrating DEGs and miRNAs enabled the identification of shared, potentially deregulated biological processes and pathways underlying the pathophysiology of AD and T2D. These common molecular mechanisms were also linked to drugs currently used in clinical practice, suggesting that this strategy may inform future drug repurposing efforts. Nonetheless, further in-depth biological validation is required to confirm these findings. Conclusion: Network medicine allowed identifying 12 miRNAs involved in the AD-T2D association, and these could be drug targets for the design of new treatments; however, the identified miRNAs need further experimental confirmation.